Find clinical trials in your area

Search by disease and location to discover available clinical trials matching your criteria.

Matched clinical trials

  • Study comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy

    Recruiting

    3 1 1 1
    Investigated drugs:
    Greece Hungary Poland Romania Spain
  • Safety and feasibility study of fecal microbiota transplant in stage II-III non-small cell lung cancer patients treated with durvalumab, carboplatin, paclitaxel and rifaximin

    Recruiting

    2 1 1 1
    Investigated diseases:
    Spain
  • Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

    Recruiting

    2 1 1 1
    Austria Czechia Denmark France Germany Greece +3
  • Study of ifinatamab deruxtecan, raludotatug deruxtecan and docetaxel in previously treated stage IV non-small cell lung cancer patients

    Recruiting

    2 1 1 1
    Germany Greece Hungary Italy Poland Spain
  • Study of telisotuzumab adizutecan with osimertinib as first treatment for adults with advanced or metastatic EGFR-mutated non-small cell lung cancer

    Recruiting

    4 1 1 1
    Investigated diseases:
    Belgium Italy Portugal Spain
  • Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

    Recruiting

    3 1 1 1
    Investigated diseases:
    Belgium France Germany Ireland Italy The Netherlands +2
  • Study of WSD0922-FU for Patients with Advanced Non-Small Cell Lung Cancer and C797S Mutation After Osimertinib Treatment

    Recruiting

    2 1 1
    Investigated diseases:
    France
  • Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

    Recruiting

    3 1 1 1
    Investigated diseases:
    Austria Belgium Bulgaria Czechia Denmark France +9
  • Study Comparing Nivolumab and Relatlimab with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients

    Recruiting

    3 1 1 1
    Austria Belgium Denmark France Germany Ireland +6
  • Study Comparing Tepotinib to Standard Treatment for Patients with Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    France